Q1 · MEDICINE
Article
Author: Eng, Heather ; Conn, Edward L. ; Lee, Esther C.-Y. ; Cokorinos, Emily C. ; Filipski, Kevin J. ; Genung, Nathan E. ; Herr, Michael ; Fernando, Dilinie P. ; Caspers, Nicole L. ; Ebner, David C. ; Feng, Bo ; Kung, Daniel W. ; Kurumbail, Ravi G. ; Reyes, Allan R. ; Kalgutkar, Amit S. ; Bhattacharya, Samit K. ; Edmonds, David J. ; Cameron, Kimberly O. ; Miller, Russell A. ; Cabral, Shawn ; Lavergne, Sophie Y. ; Borzilleri, Kris A. ; Dowling, Matthew S. ; Mathialagan, Sumathy ; Withka, Jane M. ; Ward, Jessica ; Shavnya, Andre ; Polivkova, Jana ; Panteleev, Jane ; Tu, Meihua ; Smith, Aaron C. ; Xiao, Jun ; Thuma, Benjamin A. ; Brown, Janice A. ; Salatto, Christopher T. ; Calabrese, Matthew F. ; Rajamohan, Francis ; Aspnes, Gary E. ; Li, Qifang
Optimization of the pharmacokinetic (PK) properties of a series of activators of adenosine monophosphate-activated protein kinase (AMPK) is described. Derivatives of the previously described 5-aryl-indole-3-carboxylic acid clinical candidate (1) were examined with the goal of reducing glucuronidation rate and minimizing renal excretion. Compounds 10 (PF-06679142) and 14 (PF-06685249) exhibited robust activation of AMPK in rat kidneys as well as desirable oral absorption, low plasma clearance, and negligible renal clearance in preclinical species. A correlation of in vivo renal clearance in rats with in vitro uptake by human and rat renal organic anion transporters (human OAT/rat Oat) was identified. Variation of polar functional groups was critical to mitigate active renal clearance mediated by the Oat3 transporter. Modification of either the 6-chloroindole core to a 4,6-difluoroindole or the 5-phenyl substituent to a substituted 5-(3-pyridyl) group provided improved metabolic stability while minimizing propensity for active transport by OAT3.